Literature DB >> 29386213

Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia.

Aaron C Tan1, Gavin M Marx2.   

Abstract

We present a case of cisplatin-induced syndrome of inappropriate antidiuretic hormone (SIADH) in a patient with metastatic recurrent urothelial carcinoma. Cisplatin-induced SIADH is an uncommon but potentially life-threatening toxicity. Pharmacogenetic characteristics may result in different toxicity profiles in different populations. With such widespread use of cisplatin in a diverse range of cancers, prompt recognition is crucial to detect and prevent severe neurological sequelae. © BMJ Publishing Group Ltd (unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  chemotherapy; unwanted effects / adverse reactions; urological cancer

Mesh：

Substances：

Year:  2018        PMID： 29386213      PMCID： PMC5812402          DOI： 10.1136/bcr-2017-222948

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN： 1757-790X


  26 in total

1.  Syndrome of inappropriate secretion of antidiuretic hormone induced by intraarterial cisplatin chemotherapy.

Authors:  Keisuke Ishii; Yoichi Aoki; Masaru Sasaki; Kenichi Tanaka
Journal:  Gynecol Oncol       Date:  2002-10       Impact factor: 5.482

Review 2.  A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma.

Authors:  Mariela Blum; Akihiro Suzuki; Jaffer A Ajani
Journal:  Future Oncol       Date:  2011-06       Impact factor: 3.404

3.  [Syndrome of inappropriate antidiuretic hormone secretion following cisplatinum and vindesine administration in a patient with squamous cell carcinoma of the lung].

Authors:  T Fukabori; T Nakamura; T Kida; Y Fujita; T Goto; N Hiramori; T Fujii; Y Iwasaki; M Nakagawa
Journal:  Gan To Kagaku Ryoho       Date:  1991-06

4.  Syndrome of inappropriate antidiuretic hormone secretion due to treatment of lung cancer with cisplatin.

Authors:  T J Littlewood; A P Smith
Journal:  Thorax       Date:  1984-08       Impact factor: 9.139

Review 5.  Diagnosis and management of hyponatremia in cancer patients.

Authors:  Jorge J Castillo; Marc Vincent; Eric Justice
Journal:  Oncologist       Date:  2012-05-22

6.  Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.

Authors:  U Peters; S Preisler-Adams; A Hebeisen; M Hahn; E Seifert; C Lanvers; A Heinecke; J Horst; H Jürgens; A Lamprecht-Dinnesen
Journal:  Anticancer Drugs       Date:  2000-09       Impact factor: 2.248

Review 7.  A review of drug-induced hyponatremia.

Authors:  George Liamis; Haralampos Milionis; Moses Elisaf
Journal:  Am J Kidney Dis       Date:  2008-05-12       Impact factor: 8.860

8.  Inappropriate antidiuretic syndrome hypersecretion after a single dose of cisplatin.

Authors:  Erman Atas; Vural Kesik; Abdulbaki Karaoglu; Gokhan Kalkan
Journal:  J Cancer Res Ther       Date:  2015 Oct-Dec       Impact factor: 1.805

9.  Syndrome of inappropriate secretion of antidiuretic hormone following intra-thoracic cisplatin.

Authors:  F Otsuka; Y Hayashi; T Ogura; N Hayakawa; S Ikeda; H Makino; Z Ota
Journal:  Intern Med       Date:  1996-04       Impact factor: 1.271

Review 10.  Tumor-related hyponatremia.

Authors:  Adedayo A Onitilo; Ebenezer Kio; Suhail A R Doi
Journal:  Clin Med Res       Date:  2007-12-17
View more
  2 in total

1.  Severe Hyponatremia Due to Cisplatin-induced Syndrome of Inappropriate Secretion of Antidiuretic Hormone.

Authors:  Haisam Abid; Nadir Siddiqui; Rosana Gnanajothy
Journal:  Cureus       Date:  2019-08-22

2.  Changes in hemodynamics, renal blood flow and urine output during continuous renal replacement therapies.

Authors:  S N Fernández; M J Santiago; R González; J López; M J Solana; J Urbano; J López-Herce
Journal:  Sci Rep       Date:  2020-11-27       Impact factor: 4.379
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.